Mountaingate's Relevate Exit: A Blueprint for Value in a Digital Age

DENVER, CO – August 10, 2026 – In a market often swayed by fleeting trends, the recent announcement of Mountaingate Capital’s successful exit from its investment in Relevate Health serves as a powerful case study in building permanent value. While any private equity exit is notable, this transaction stands out not merely for its success, but for what it validates: a disciplined, repeatable strategy for transforming lower middle-market companies into resilient industry leaders. The sale marks the culmination of a four-year partnership that saw Relevate Health evolve into a dominant force in healthcare commercialization, offering a clear blueprint for how strategic capital and operational expertise can forge a winner in a complex sector.

For observers seeking to understand the mechanics of consistent value creation, the Mountaingate-Relevate story is more than just a deal announcement. It is a lesson in identifying underlying market forces, executing a methodical growth plan, and building an enterprise that lasts beyond a single investment cycle. This exit is another notch in the firm’s belt, reinforcing its reputation as a premier partner for founders in the tech-enabled services space.

The Repeatable Playbook for Building Winners

Mountaingate Capital’s success with Relevate Health is not an isolated event; it is the product of a well-honed investment thesis. The Denver-based firm, now managing over $1.4 billion in assets after closing its third fund, has carved out a distinct niche by focusing on a “founder-friendly” and customer-centric “buy-and-build” model. Rather than imposing a rigid top-down structure, Mountaingate partners with entrepreneurial management teams, aligning on an ambitious growth vision and providing the capital and strategic support to execute it.

This playbook has proven particularly potent in the tech-enabled, data-driven marketing services sector. The Relevate exit follows a string of highly successful outcomes for Mountaingate, including its divestitures of Tinuiti (2020), a performance marketing powerhouse; Bounteous (2021), a digital transformation agency; and Mars United Commerce (2024), a commerce marketing agency acquired by Publicis Groupe. In each case, the pattern is remarkably consistent: partner with a strong foundational company, accelerate organic growth, and execute a series of strategic add-on acquisitions to build a comprehensive, market-leading platform. During its partnership with Mountaingate, Tinuiti grew its employee base by over 400%, while Mars United Commerce expanded by over 200%.

Relevate Health fit perfectly into this framework. When Mountaingate invested in 2020, it saw a company with a strong core but with the potential to become a true platform leader. The firm’s approach provided not just capital, but a strategic roadmap. “We aligned with Mountaingate around an ambitious shared vision for growth and they steadfastly supported that plan,” commented Jeff Spanbauer, Relevate's Co-founder and Chairman. His sentiment underscores the collaborative nature of the partnership, which he noted reinforced the company's culture—a critical element for sustainable growth.

From Partnership to Platform Leadership

The transformation of Relevate Health between 2020 and 2024 is a testament to the power of this buy-and-build strategy. The journey began with a clear goal: to create a premier healthcare commercialization platform for the pharmaceutical industry. This was achieved through a combination of internal investment and four highly strategic acquisitions that dramatically expanded Relevate's capabilities and market reach.

Among the most pivotal moves was the 2020 merger with Arteric, a digital marketing agency renowned for its machine learning-driven approach. This immediately infused Relevate with sophisticated data science and multichannel marketing capabilities. The subsequent 2022 acquisition of ConneXion360 further solidified its leadership position, adding a suite of tools for engaging Healthcare Professionals (HCPs) at the crucial points of care and prescribing. With this move, Relevate expanded its service to over 185 brands from 90 different manufacturers.

Parallel to these acquisitions, Mountaingate fueled significant investment in Relevate’s proprietary technology, the ELE Decision Engine®. This platform is the company’s central nervous system, combining advanced analytics, AI, and first-party healthcare data to help clients deliver precisely targeted messages. It allows life sciences organizations to move beyond broad-stroke marketing to a truly data-driven commercialization strategy. As Relevate CEO Tim Pantello stated, Mountaingate's investment “helped strengthen our platform, expand our capabilities, and position the company for this exciting next phase.” The result is a comprehensive, independent platform that offers everything from commercial strategy and medical communications to omnichannel marketing and advanced analytics, helping clients accelerate performance and improve patient outcomes.

Reading the Signals in Healthcare's Digital Shift

The Mountaingate-Relevate exit does not exist in a vacuum. It is a significant barometer for the rapidly evolving healthcare commercialization landscape. The pharmaceutical, biotechnology, and medical device industries are under immense pressure to adapt to a world where digital engagement is paramount and demonstrating return on investment is non-negotiable. The days of relying solely on traditional sales forces are over; today's environment demands sophisticated, data-driven, and omnichannel strategies to effectively reach both HCPs and patients.

This shift has created fertile ground for platforms like Relevate Health. The market for healthcare marketing services has historically been fragmented, with a patchwork of specialized agencies. Mountaingate’s strategy of consolidating complementary services under one roof directly addresses a core market need for integrated, end-to-end solutions. Life sciences companies are increasingly seeking partners who can provide a holistic view of the commercialization process, powered by technology that can measure and optimize every interaction.

This transaction, advised by Houlihan Lokey, signals strong investor confidence in businesses that can master this complexity. The high value placed on tech-enabled platforms that promise measurable outcomes is a clear trend, attracting significant private equity interest to the marketing services sector. For his part, Bruce Rogers, Co-Founder and Managing Director of Mountaingate, expressed his confidence in the company’s future, noting, “We have no doubt they will continue to set the standard within the pharmaceutical commercialization space.” This successful exit validates Relevate Health’s formidable market position and underscores the enduring power of a strategic vision executed with discipline.